Company intelligence / Profile preview

Arpeggi

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Arpeggio is developing a platform to drug transcription factors historically considered undruggable. The company has demonstrated proof-of-concept through partnerships with Johnson & Johnson and FORMA Therapeutics, with Phase I clinical achievements in rare disease and inflammation. Lead programs are advancing toward clinical development, including an NRF2 degrader that showed regression of aggressive adenocarcinoma tumors in vivo.

Therapeutic areas: OncologyNephrologyNeurology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Partnerships

Johnson & JohnsonFORMA Therapeutics

Beyond the preview

Go deeper on Arpeggi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arpeggi.

Explore the full profile